A New Subtype-Specific Monoclonal Antibody for IAP-survivin Identifies High-Risk Patients With Diffuse Large B-Cell Lymphoma and Improves the Prognostic Value of BCL-2

International Journal of Oncology - Greece
doi 10.3892/ijo.32.1.59
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

BCL-2 Protein Frequency in Patients With High-Risk Diffuse Large B-Cell Lymphoma

Sao Paulo Medical Journal
Medicine
2010English

Combination of BCL-2 and MYC Protein Expression Improves High-Risk Stratification in Diffuse Large B-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2015English

Prognostic Value of Baseline FDG Pet Parameters in High Risk Diffuse Large B-Cell Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Prognostic Nomogram for Overall Survival in Patients With Diffuse Large B‐Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2019English

Plasma Immunoprofiling of Patients With High-Risk Diffuse Large B-Cell Lymphoma: A Nordic Lymphoma Group Study

Blood Cancer Journal
OncologyHematology
2016English

Blood Lymphocyte-To-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated With R-Chop

PLoS ONE
Multidisciplinary
2012English

Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and CHOP

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2010English

Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

The Kyoto Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma in the Rituximab Era

Blood
BiochemistryImmunologyCell BiologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy